WE HAVE A FOCUSED DISCOVERY & DEVELOPMENT PROCESS

OUR TARGETED APPROACH IS KEY TO OUR SUCCESS

VALIDATE

known cancer targets, focusing on CDKs

DISCOVER

the best small molecules to interact with those targets

EVALUATE

new compounds for safety and efficacy

TRIAL

new compounds through global clinical trials in collaboration with partners

REALISE IMPACT

with partners through global sales and patient treatment

RESEARCH & DEVELOPMENT

Aucentra’s deep pipeline of novel anticancer drug candidates are delivering world-firsts.

Aucentra discovers and develops novel small molecule candidates for oncology targets, focusing on the kinase family. Over 500 known kinases are encoded in the human genome, which maintain cellular function by switching on pathways such as cell signalling and metabolism. The inhibition of kinases is a proven approach to addressing cancer resistance.

Cyclin Dependent Kinases (CDKs) are particularly important for cellular proliferation, due to their involvement in regulation of the cell cycle and transcription. CDKs are overly activated in more than 80% of all human cancer types, making them excellent targets for innovative therapeutics.

We are experts in drug discovery and development and in particular, kinase inhibitors for oncology. Our unique capabilities in target validation, drug design, medicinal chemistry, cancer biology and in vivo pharmacology enable us to rapidly develop novel inhibitor compounds that are highly potent and selective. We are able to demonstrate their safety and efficacy in our advanced in vivo and in vitro cancer models, and fast-track candidates to the clinic.

Our current pipeline has several drug molecules in preclinical and clinical development stages in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients.

MEET OUR R&D TEAM

Professor Shudong Wang

Professor Shudong Wang

Chief Scientific Officer

Dr Mingfeng Yu

Dr Mingfeng Yu

Medicinal Chemistry

Dr Yi Long

Dr Yi Long

Medicinal Chemistry

Dr Aik Goh

Dr Aik Goh

Medicinal Chemistry

Dr Ahmed Abdelaziz

Dr Ahmed Abdelaziz

Medicinal Chemistry

Dr Sunita Basnet

Dr Sunita Basnet

Cell Biology and Biochemistry

Dr Theodosia Teo

Dr Theodosia Teo

Structure Biology and Cancer Cell Biology

Dr Muhammed Rahaman

Dr Muhammed Rahaman

Cancer Cell Biology and Animal Pharmacology

Dr Laychiluh Mekonnen

Dr Laychiluh Mekonnen

Cancer Cell Biology and Animal Pharmacology

Ben Noll

Ben Noll

Pharmacokinetic

KEY RESEARCH PUBLICATIONS

Tadesse, S, Anshabo, AT, Portman, N, Lim, E, Tilley, W, Caldon, CE, Wang, S (2019) Targeting CDK2 in cancer: challenges and opportunities for therapy, Drug Discovery Today.

Rahaman, MH, Lam, F, Zhong, L, Teo, T, Adams, J, Yu, M, Milne, RW, Pepper, C, Lokman, NA, Ricciardelli, C, Oehler, MK & Wang, S (2019) Targeting CDK9 for treatment of colorectal cancer, Molecular Oncology, vol.13, no. 10, pp. 2178-2193.

Rahaman, MH, Yu, Y, Zhong, L, Adams, J, Lam, F, Li, P, Noll, B, Milne, R, Peng, J & Wang, S (2019) CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia, Investigational New Drugs, vol. 37, no. 4, pp. 625-635.

Tadesse, S, Caldon, E.C., Tilley, W., Wang, S. (2019) Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update, Journal of Medicinal Chemistry, vol. 62, no 9, pp. 4233-4251.

Philip, S, Kumarasiri, M, Teo, T, Yu, M & Wang, S (2018) Cyclin-dependent kinase 8: a new hope in targeted cancer therapy?, Journal of Medicinal Chemistry, vol. 61, no. 12, pp. 5073-5092.

Tadesse, S, Bantie, L, Tomusange, K, Yu, M, Islam, S, Bykovska, N, Noll, B, Zhu, G, Li, P, Lam, F, Kumarasiri, M, Milne, R & Wang, S (2018) Discovery and pharmacological characterisation of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents, British Journal of Pharmacology, vol. 175, no. 12, pp. 2399-2413.

Cao, S, Yu, Y, Chen, S, Lei, D, Wang, S, Pan, X & Peng, J (2017) Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells, Biochemical and Biophysical Research Communications, vol. 482, no. 4, pp. 536-541.

Kumarasiri, M, Teo, T, Yu, M, Philip, S, Basnet, SK, Albrecht, H, Sykes, MJ, Wang, P & Wang, S (2017) In search of novel CDK8 inhibitors by virtual screening, Journal of Chemical Information and Modeling, vol. 57, no. 3, pp. 413-416.

Tadesse, S, Zhu, G, Mekonnen, LB, Lenjisa, JL, Yu, M, Brown, MP & Wang, S (2017) A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors, Future Medicinal Chemistry, vol. 9, no. 13, pp. 1495-1506.

Zeleke, S, Yu, M, Mekonnen, LB, Lam, F, Islam, S, Tomusange, K, Rahaman, MH, Noll, B, MC Basnet, S, Teo, T, Albrecht, H, Milne, R & Wang, S (2017) Highly potent, selective, and orally bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation, Journal of Medicinal Chemistry, vol. 60, no. 5, pp. 1892-1915.

Rahaman, MH, Kumarasiri, M, Mekonnen, LB, Yu, M, Diab, S, Albrecht, H, Milne, RW & Wang, S (2016) Targeting CDK9: a promising therapeutic opportunity in prostate cancer, Endocrine-Related Cancer, vol. 23, no. 12, pp. T211-T226.

© 2020 AUCENTRA

Lab and Building image photography by Chris Oaten.